Literature DB >> 1612788

Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer.

A Douvdevani1, M Huleihel, M Zöller, S Segal, R N Apte.   

Abstract

Interleukin-1 (IL-1) is a major immunoregulatory/proinflammatory cytokine which also affects fibroblast proliferation and function and therefore it was of interest to investigate whether its constitutive expression influences the in vivo tumorigenic potential of transformed fibroblastoid cell lines. Here we report on a strong correlation between the constitutive expression of IL-1 alpha and reduced tumorigenicity, using various series of oncogene-transformed NIH/3T3-derived cell lines which produce the cytokine spontaneously or upon gene transfer, following transfection with the IL-1 alpha cDNA. Reduced tumorigenicity of the constitutive IL-1 alpha producing cell lines was manifested either by inability to grow in animals or by regressions of initially growing tumors, within 2 to 3 weeks from cell inoculation. In contrast, mice inoculated with non-IL-1-producing cell lines developed progressive tumors which ultimately killed the animals. Clones obtained from a non-IL-1-producing met-transformed cell line shifted from a progressive to a regressive phenotype, following transfection with an IL-1 alpha-encoding gene, inserted into an appropriate expression vector, resulting in constitutive expression of the cytokine. The effects of constitutive IL-1 expression on tumor development were observed both in histocompatible (NFS/N) and partially allogeneic (BALB/c) mice; however, they were more pronounced in the allogeneic environment. Fibrosarcomas which are non-IL-1 producers induced progressive tumors in both strains of mice at the same growth rate. The differences between the growth characteristics of the fibrosarcomas in histocompatible vs. partially allogenic mice suggest that IL-1 exerts adjuvant-like effects which increase the immunogenicity of tumor-cell antigens, and they also argue against the possibility that an IL-1-mediated local non-specific inflammatory response is the major effector mechanism of tumor rejection. Indeed, in subsequent studies we shall report on the importance of specific cellular immune responses, especially cytotoxic T lymphocytes (CTLs), in the eradication of constitutive IL-1-producing fibrosarcomas. Thus, our findings may serve as the basis for novel immunotherapy strategies aimed at the induction of IL-1 expression by cells comprising the neoplasm or alternatively by local application of the cytokine in the vicinity of the tumor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1612788     DOI: 10.1002/ijc.2910510526

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis.

Authors:  Maryse Dagenais; Jeremy Dupaul-Chicoine; Todd Douglas; Claudia Champagne; Alexandre Morizot; Maya Saleh
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  Mechanisms of cytokine production by fibroblasts-implications for normal connective tissue homeostasis and pathological conditions.

Authors:  R N Apte
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

3.  IL-1 is required for tumor invasiveness and angiogenesis.

Authors:  Elena Voronov; Dror S Shouval; Yakov Krelin; Emanuela Cagnano; Daniel Benharroch; Yoichiro Iwakura; Charles A Dinarello; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 11.205

Review 4.  Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies.

Authors:  Konstantinos Rounis; Dimitrios Makrakis; Ioannis Gioulbasanis; Simon Ekman; Luigi De Petris; Dimitris Mavroudis; Sofia Agelaki
Journal:  Life (Basel)       Date:  2022-06-12

5.  Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Authors:  Suresh Kumar; Hiromitsu Kishimoto; Hui Lin Chua; Sunil Badve; Kathy D Miller; Robert M Bigsby; Harikrishna Nakshatri
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 6.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

7.  Tumorigenicity of IL-1alpha- and IL-1beta-deficient fibrosarcoma cells.

Authors:  Irina Nazarenko; Rachid Marhaba; Eli Reich; Elena Voronov; Mario Vitacolonna; Dagmar Hildebrand; Elena Elter; Mohini Rajasagi; Ron N Apte; Margot Zöller
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

Review 8.  Function and regulation of IL-1α in inflammatory diseases and cancer.

Authors:  Ankit Malik; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

9.  Overexpression of Interleukin-1α Suppresses Liver Metastasis of Lymphoma: Implications for Antitumor Effects of CD8+ T-cells.

Authors:  Kazuhiko Udagawa; Yasuo Niki; Toshiyuki Kikuchi; Yusuke Fukuhara; Yuki Takeda; Takeshi Miyamoto; Morio Matsumoto; Masaya Nakamura
Journal:  J Histochem Cytochem       Date:  2021-02-09       Impact factor: 2.479

10.  Enhanced immune response with foot and mouth disease virus VP1 and interleukin-1 fusion genes.

Authors:  Jong Hyeon Park; Sun Jin Kim; Jae Ku Oem; Kwang Nyeong Lee; Yong Joo Kim; Soo Jeong Kye; Jee Yong Park; Yi Seok Joo
Journal:  J Vet Sci       Date:  2006-09       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.